Loading content…
ConditionICD-10: G47.33
Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a sleep disorder where breathing repeatedly stops and starts because the airway collapses during sleep. It affects an estimated 30 million US adults, contributes to cardiovascular disease, daytime fatigue, and reduced quality of life — and is closely linked to obesity, with weight loss often dramatically improving symptoms. The FDA approved Zepbound (tirzepatide) in December 2024 specifically for moderate-to-severe OSA in adults with obesity, making it the first GLP-1 with this on-label indication.
Key facts
- •~30 million US adults have OSA; 80%+ are undiagnosed (American Academy of Sleep Medicine)
- •OSA prevalence is 2-4x higher in adults with obesity (BMI ≥30)
- •Zepbound (tirzepatide) FDA-approved Dec 2024 for moderate-severe OSA + obesity
- •In the SURMOUNT-OSA trial, tirzepatide reduced apnea-hypopnea index (AHI) by ~25-29 events/hour
- •Weight loss of 10% can reduce OSA severity by 30-50% even without medication
- •OSA increases risk of stroke, heart attack, atrial fibrillation, and type 2 diabetes
Why GLP-1 medications
OSA pathophysiology is driven significantly by excess soft tissue in upper airway and around the pharynx — both reduced by weight loss. GLP-1 medications produce 15-22% body-weight reduction, which directly decompresses the airway and reduces apnea events. The SURMOUNT-OSA trials (published 2024 NEJM) showed tirzepatide reduced AHI by ~25-29 events/hour at 52 weeks, with 43% of patients reaching the threshold for OSA resolution. Beyond the direct airway effect, GLP-1 also improves the metabolic profile (insulin resistance, inflammation) that worsens OSA outcomes.
